# Allecra Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allecra-therapeutics

- Industry: Pharmaceuticals
- Headquarters: France
- Website: www.allecra.com
- Total disclosed funding: $44M
- Latest round: Series B (Jun 15, 2016)
- Investors on record: 5

## About

Allecra Therapeutics is a biopharmaceutical company focused on developing innovative therapies to combat antibiotic resistance, particularly through its lead product candidate targeting complicated urinary tract infections.Founded in 2013 in France, Allecra Therapeutics specializes in the development of therapies addressing antibiotic resistance. The company raised EUR 22 million in Series B financing on June 15, 2016, led by Delos Capital Partners, with participation from returning investors. The founder, Nicholas Benedict, has a history in the life sciences sector, although specific previous ventures are not detailed. Allecra has engaged in two significant deals since its inception.Allecra Therapeutics specializes in developing innovative therapies targeting antibiotic resistance, particularly with its lead product candidate, cefepime/enmetazobactam. This antibiotic provides a critical treatment option for complicated urinary tract infections (cUTIs) caused by Extended-Spectrum ß-lactamase (ESBL)-producing pathogens. Clinical trials indicate it outperforms standard treatments, aiming to meet the urgent healthcare challenge of antibiotic resistance. The product is primarily aimed at hospitals and healthcare providers in the United States and Europe, where antibiotic-resistant infections are prevalent.In the most recent year, 2023, Allecra Therapeutics reported a revenue of EUR 2,480,739.50 with a negative EBITDA of EUR -710,378.90. The company generates revenue through partnerships and licensing agreements related to its flagship antibiotic, cefepime/enmetazobactam, and is preparing submissions for marketing approval to facilitate sales and distribution.Allecra Therapeutics plans to expand its product portfolio with new antibiotic therapies while targeting key markets in Europe and North America by 2025. The EUR 22 million raised in their Series B financing will support these initiatives, including the development of cefepime/enmetazobactam. The company aims to broaden its market access through strategic partnerships and licensing agreements, enhancing distribution channels across healthcare providers and hospitals.

## Funding rounds

- Series B, Jun 15, 2016, $25M — Andera Partners, EMBL Ventures, Forbion, Delos Capital Partners
- Series A, Apr 18, 2013, $20M — EMBL Ventures, Forbion, Edmond de Rothschild Asset Management

## Investors

- EMBL Ventures (https://capitalatlas.ai/funds/embl-ventures) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B
- Edmond de Rothschild Asset Management (https://capitalatlas.ai/funds/edmond-de-rothschild-asset-management) — Series A
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series B